查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1602396

急性冠狀動脈症候群市場：按類型、產品和最終用戶分類 - 全球預測 2025-2030

Acute Coronary Syndrome Market by Type (Non-St-Elevation Myocardial Infarction (NSTEMI), St-Elevation Myocardial Infarction (STEMI), Unstable Angina), Offering (Blood Tests, Imaging, Stress Test), End User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 184 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年，急性冠狀動脈症候群市場價值為18.2億美元，預計到2024年將達到19.4億美元，複合年成長率為6.76%，到2030年將達到28.9億美元。

急性冠狀動脈症候群(ACS) 包括多種​​涉及心臟血流量突然減少的病症，通常以胸痛和不適為特徵。 ACS 包括心肌梗塞和不穩定型心絞痛，其嚴重性和日益增加的盛行率需要準確的市場分析。 ACS 的早期診斷和治療對於降低發病率和死亡率至關重要，這凸顯了先進診斷工具和治療性介入的應用。最終用途範圍主要包括醫院、門診醫療中心和配備新技術以有效對抗 ACS 的診斷實驗室。該市場受到老年人口成長、生活方式相關風​​險因素發生率增加以及基於生物標記和就地檢驗等醫療技術進步的強烈影響。個人化醫療的進步、預測分析人工智慧的整合以及支架技術和藥物治療的創新都存在機會。成長的障礙包括治療成本上升、嚴格的法律規範以及發展中地區的准入有限。為了利用這些機會，公司可以專注於策略夥伴關係關係，探索用於風險評估的基因分析，並開拓適合新興市場的具有成本效益的解決方案。非侵入性診斷、穿戴式監測設備和改進的藥物傳輸系統等領域的創新可能會蓬勃發展。隨著對卓越的患者治療效果和醫療保健服務效率的不斷追求，市場競爭激烈，顛覆的時機已經成熟。公司還必須適應向基於價值的護理模式的轉變，強調整體患者體驗和長期健康效益。透過利用技術並專注於以患者為中心的創新，相關人員可以克服挑戰並有效推動 ACS 領域的市場成長。

主要市場統計
基準年[2023] 18.2億美元
預測年份 [2024] 19.4億美元
預測年份 [2030] 28.9億美元
複合年成長率（%） 6.76%

市場動態：快速發展的急性冠狀動脈症候群市場的關鍵市場洞察

供應和需求的動態交互作用正在改變急性冠狀動脈症候群市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時也能幫助企業了解消費行為及其對製造業的影響。

  • 市場促進因素
    • 全球心血管疾病盛行率不斷上升
    • 傾向於疾病的早期診斷和治療
    • 藥物發現和藥物開發流程的增加
  • 市場限制因素
    • 急性冠狀動脈症候群的治療費用上漲
  • 市場機會
    • 急性冠狀動脈症候群治療進展
    • 持續研究和開發以改善急性冠狀動脈症候群的診斷設備和治療方法
  • 市場挑戰
    • 急性冠狀動脈症候群藥物和器械核准的嚴格監管要求

波特五力：駕馭急性冠狀動脈症候群市場的策略工具

波特的五力框架是了解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解急性冠狀動脈症候群市場的外部影響

外部宏觀環境因素在塑造急性冠狀動脈症候群市場的表現動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析 了解急性冠狀動脈症候群市場的競爭格局

對急性冠狀動脈症候群市場的詳細市場佔有率分析可以對供應商的績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣急性冠狀動脈症候群市場供應商的績效評估

FPNV 定位矩陣是評估急性冠狀動脈症候群市場供應商的關鍵工具。此矩陣允許業務組織根據供應商的商務策略和產品滿意度評估供應商，從而做出符合其目標的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析和建議描繪了急性冠狀動脈症候群市場的成功之路

急性冠狀動脈症候群市場的策略分析對於旨在加強其在全球市場的影響力的公司至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機，並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：對當前市場環境的詳細審查、主要企業的廣泛資料、對其在市場中的影響力和整體影響力的評估。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 全球心血管疾病盛行率增加
      • 疾病的早​​期診斷和治療趨勢
      • 改進藥物發現和開發流程
    • 抑制因素
      • 急性冠狀動脈症候群的治療費用上漲
    • 機會
      • 急性冠狀動脈症候群的治療進展
      • 正在進行的研究和開發旨在改進急性冠狀動脈症候群的診斷設備和治療
    • 任務
      • 核准治療急性冠狀動脈症候群的藥物和器械的嚴格監管要求
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章急性冠狀動脈症候群市場：依類型

  • 非中心抬高型心肌梗塞 (NSTEMI)
  • ST 段上升型心肌梗塞 (STEMI)
  • 不穩定型心絞痛

第7章急性冠狀動脈症候群市場：透過提供

  • 驗血
  • 影像
  • 壓力測試

第8章急性冠狀動脈症候群市場：依最終用戶分類

  • 學術機構
  • 診斷中心
  • 醫院/診所

第9章美洲急性冠狀動脈症候群市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第10章亞太地區急性冠狀動脈症候群市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第11章 歐洲、中東和非洲急性冠狀動脈症候群市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第12章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • Abbott Laboratories
  • Amgen Inc.
  • AstraZeneca PLC
  • Baxter International, Inc.
  • Bayer AG
  • bioMerieux SA
  • Boehringer Ingelheim International GmbH
  • Boston Scientific Corporation
  • DAIICHI SANKYO COMPANY, LIMITED
  • Dr. Reddy's Laboratories Ltd.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • Gilead Sciences, Inc.
  • Johnson & Johnson Service, Inc.
  • Koninklijke Philips NV
  • Medtronic PLC
  • Merck & Co, Inc.
  • Novartis AG
  • Pfizer Inc.
  • Regeneron Pharmaceuticals Inc.
  • Sanofi SA
  • Siemens AG
  • Terumo Corporation
  • Teva Pharmaceutical Industries Ltd.
Product Code: MRR-C002B1C99761

The Acute Coronary Syndrome Market was valued at USD 1.82 billion in 2023, expected to reach USD 1.94 billion in 2024, and is projected to grow at a CAGR of 6.76%, to USD 2.89 billion by 2030.

Acute Coronary Syndrome (ACS) encompasses a spectrum of conditions associated with sudden, reduced blood flow to the heart, typically characterized by chest pain or discomfort. It includes conditions such as myocardial infarction and unstable angina, demanding precise market analysis due to its critical nature and increasing prevalence. The necessity of early diagnosis and treatment of ACS is vital to reduce morbidity and mortality rates, highlighting the application of advanced diagnostic tools and therapeutic interventions. The end-use scope primarily involves hospitals, ambulatory care centers, and diagnostic laboratories armed with emerging technologies to combat ACS effectively. The market is strongly influenced by the growing geriatric population, increasing incidence of lifestyle-related risk factors, and advancements in medical technology such as biomarker-based tests and point-of-care testing. Opportunities lie in the development of personalized medicine, integration of artificial intelligence for predictive analytics, and innovations in stent technology and pharmacotherapy. Barriers to growth include high costs of treatment, stringent regulatory frameworks, and limited accessibility in developing regions. To capitalize on these opportunities, companies can focus on strategic partnerships, research in genetic profiling for risk assessment, and the development of cost-effective solutions tailored to emerging markets. Innovation can flourish in areas like non-invasive diagnostic methods, wearable monitoring devices, and improved drug delivery systems. The market nature is highly competitive yet ripe for disruption with a constant push towards superior patient outcomes and efficiency in healthcare delivery. Companies must also adapt to the shift towards value-based care models, emphasizing overall patient experiences and long-term health benefits. By leveraging technology and focusing on patient-centric innovation, stakeholders can navigate the challenges and propel market growth in the ACS sector effectively.

KEY MARKET STATISTICS
Base Year [2023] USD 1.82 billion
Estimated Year [2024] USD 1.94 billion
Forecast Year [2030] USD 2.89 billion
CAGR (%) 6.76%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Acute Coronary Syndrome Market

The Acute Coronary Syndrome Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing prevalence of cardiovascular diseases worldwide
    • Inclination toward early diagnosis and treatment of diseases
    • Rise in drug discovery and drug development process
  • Market Restraints
    • High cost of treatment of acute-coronary-syndrome
  • Market Opportunities
    • Advancements in the treatment of acute-coronary-syndrome
    • Ongoing R&D for development of enhanced diagnostic devices and treatment for acute-coronary-syndrome
  • Market Challenges
    • Stringent regulatory requirement for approval of drugs and devices for acute-coronary-syndrome treatment

Porter's Five Forces: A Strategic Tool for Navigating the Acute Coronary Syndrome Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Acute Coronary Syndrome Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Acute Coronary Syndrome Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Acute Coronary Syndrome Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Acute Coronary Syndrome Market

A detailed market share analysis in the Acute Coronary Syndrome Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Acute Coronary Syndrome Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Acute Coronary Syndrome Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Acute Coronary Syndrome Market

A strategic analysis of the Acute Coronary Syndrome Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Acute Coronary Syndrome Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Amgen Inc., AstraZeneca PLC, Baxter International, Inc., Bayer AG, bioMerieux SA, Boehringer Ingelheim International GmbH, Boston Scientific Corporation, DAIICHI SANKYO COMPANY, LIMITED, Dr. Reddy's Laboratories Ltd., Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Gilead Sciences, Inc., Johnson & Johnson Service, Inc., Koninklijke Philips N.V., Medtronic PLC, Merck & Co, Inc., Novartis AG, Pfizer Inc., Regeneron Pharmaceuticals Inc., Sanofi S.A., Siemens AG, Terumo Corporation, and Teva Pharmaceutical Industries Ltd..

Market Segmentation & Coverage

This research report categorizes the Acute Coronary Syndrome Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type, market is studied across Non-St-Elevation Myocardial Infarction (NSTEMI), St-Elevation Myocardial Infarction (STEMI), and Unstable Angina.
  • Based on Offering, market is studied across Blood Tests, Imaging, and Stress Test.
  • Based on End User, market is studied across Academic Institutes, Diagnostic Centers, and Hospitals & Clinics.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of cardiovascular diseases worldwide
      • 5.1.1.2. Inclination toward early diagnosis and treatment of diseases
      • 5.1.1.3. Rise in drug discovery and drug development process
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of treatment of acute-coronary-syndrome
    • 5.1.3. Opportunities
      • 5.1.3.1. Advancements in the treatment of acute-coronary-syndrome
      • 5.1.3.2. Ongoing R&D for development of enhanced diagnostic devices and treatment for acute-coronary-syndrome
    • 5.1.4. Challenges
      • 5.1.4.1. Stringent regulatory requirement for approval of drugs and devices for acute-coronary-syndrome treatment
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Acute Coronary Syndrome Market, by Type

  • 6.1. Introduction
  • 6.2. Non-St-Elevation Myocardial Infarction (NSTEMI)
  • 6.3. St-Elevation Myocardial Infarction (STEMI)
  • 6.4. Unstable Angina

7. Acute Coronary Syndrome Market, by Offering

  • 7.1. Introduction
  • 7.2. Blood Tests
  • 7.3. Imaging
  • 7.4. Stress Test

8. Acute Coronary Syndrome Market, by End User

  • 8.1. Introduction
  • 8.2. Academic Institutes
  • 8.3. Diagnostic Centers
  • 8.4. Hospitals & Clinics

9. Americas Acute Coronary Syndrome Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Acute Coronary Syndrome Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Acute Coronary Syndrome Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. Amgen Inc.
  • 3. AstraZeneca PLC
  • 4. Baxter International, Inc.
  • 5. Bayer AG
  • 6. bioMerieux SA
  • 7. Boehringer Ingelheim International GmbH
  • 8. Boston Scientific Corporation
  • 9. DAIICHI SANKYO COMPANY, LIMITED
  • 10. Dr. Reddy's Laboratories Ltd.
  • 11. Eli Lilly and Company
  • 12. F. Hoffmann-La Roche Ltd.
  • 13. Gilead Sciences, Inc.
  • 14. Johnson & Johnson Service, Inc.
  • 15. Koninklijke Philips N.V.
  • 16. Medtronic PLC
  • 17. Merck & Co, Inc.
  • 18. Novartis AG
  • 19. Pfizer Inc.
  • 20. Regeneron Pharmaceuticals Inc.
  • 21. Sanofi S.A.
  • 22. Siemens AG
  • 23. Terumo Corporation
  • 24. Teva Pharmaceutical Industries Ltd.

LIST OF FIGURES

  • FIGURE 1. ACUTE CORONARY SYNDROME MARKET RESEARCH PROCESS
  • FIGURE 2. ACUTE CORONARY SYNDROME MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL ACUTE CORONARY SYNDROME MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL ACUTE CORONARY SYNDROME MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL ACUTE CORONARY SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL ACUTE CORONARY SYNDROME MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL ACUTE CORONARY SYNDROME MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL ACUTE CORONARY SYNDROME MARKET SIZE, BY OFFERING, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL ACUTE CORONARY SYNDROME MARKET SIZE, BY OFFERING, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL ACUTE CORONARY SYNDROME MARKET SIZE, BY END USER, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL ACUTE CORONARY SYNDROME MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS ACUTE CORONARY SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS ACUTE CORONARY SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES ACUTE CORONARY SYNDROME MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES ACUTE CORONARY SYNDROME MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC ACUTE CORONARY SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC ACUTE CORONARY SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA ACUTE CORONARY SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA ACUTE CORONARY SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. ACUTE CORONARY SYNDROME MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. ACUTE CORONARY SYNDROME MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. ACUTE CORONARY SYNDROME MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL ACUTE CORONARY SYNDROME MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ACUTE CORONARY SYNDROME MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL ACUTE CORONARY SYNDROME MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. ACUTE CORONARY SYNDROME MARKET DYNAMICS
  • TABLE 7. GLOBAL ACUTE CORONARY SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL ACUTE CORONARY SYNDROME MARKET SIZE, BY NON-ST-ELEVATION MYOCARDIAL INFARCTION (NSTEMI), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL ACUTE CORONARY SYNDROME MARKET SIZE, BY ST-ELEVATION MYOCARDIAL INFARCTION (STEMI), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL ACUTE CORONARY SYNDROME MARKET SIZE, BY UNSTABLE ANGINA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL ACUTE CORONARY SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL ACUTE CORONARY SYNDROME MARKET SIZE, BY BLOOD TESTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL ACUTE CORONARY SYNDROME MARKET SIZE, BY IMAGING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL ACUTE CORONARY SYNDROME MARKET SIZE, BY STRESS TEST, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL ACUTE CORONARY SYNDROME MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL ACUTE CORONARY SYNDROME MARKET SIZE, BY ACADEMIC INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL ACUTE CORONARY SYNDROME MARKET SIZE, BY DIAGNOSTIC CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL ACUTE CORONARY SYNDROME MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. AMERICAS ACUTE CORONARY SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 20. AMERICAS ACUTE CORONARY SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS ACUTE CORONARY SYNDROME MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS ACUTE CORONARY SYNDROME MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 23. ARGENTINA ACUTE CORONARY SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 24. ARGENTINA ACUTE CORONARY SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 25. ARGENTINA ACUTE CORONARY SYNDROME MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 26. BRAZIL ACUTE CORONARY SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 27. BRAZIL ACUTE CORONARY SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 28. BRAZIL ACUTE CORONARY SYNDROME MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 29. CANADA ACUTE CORONARY SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 30. CANADA ACUTE CORONARY SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 31. CANADA ACUTE CORONARY SYNDROME MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 32. MEXICO ACUTE CORONARY SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 33. MEXICO ACUTE CORONARY SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 34. MEXICO ACUTE CORONARY SYNDROME MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 35. UNITED STATES ACUTE CORONARY SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 36. UNITED STATES ACUTE CORONARY SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 37. UNITED STATES ACUTE CORONARY SYNDROME MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 38. UNITED STATES ACUTE CORONARY SYNDROME MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 39. ASIA-PACIFIC ACUTE CORONARY SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 40. ASIA-PACIFIC ACUTE CORONARY SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 41. ASIA-PACIFIC ACUTE CORONARY SYNDROME MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 42. ASIA-PACIFIC ACUTE CORONARY SYNDROME MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 43. AUSTRALIA ACUTE CORONARY SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 44. AUSTRALIA ACUTE CORONARY SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 45. AUSTRALIA ACUTE CORONARY SYNDROME MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 46. CHINA ACUTE CORONARY SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 47. CHINA ACUTE CORONARY SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 48. CHINA ACUTE CORONARY SYNDROME MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 49. INDIA ACUTE CORONARY SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 50. INDIA ACUTE CORONARY SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 51. INDIA ACUTE CORONARY SYNDROME MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 52. INDONESIA ACUTE CORONARY SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 53. INDONESIA ACUTE CORONARY SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 54. INDONESIA ACUTE CORONARY SYNDROME MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 55. JAPAN ACUTE CORONARY SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 56. JAPAN ACUTE CORONARY SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 57. JAPAN ACUTE CORONARY SYNDROME MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 58. MALAYSIA ACUTE CORONARY SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 59. MALAYSIA ACUTE CORONARY SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 60. MALAYSIA ACUTE CORONARY SYNDROME MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 61. PHILIPPINES ACUTE CORONARY SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. PHILIPPINES ACUTE CORONARY SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 63. PHILIPPINES ACUTE CORONARY SYNDROME MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 64. SINGAPORE ACUTE CORONARY SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 65. SINGAPORE ACUTE CORONARY SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 66. SINGAPORE ACUTE CORONARY SYNDROME MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 67. SOUTH KOREA ACUTE CORONARY SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. SOUTH KOREA ACUTE CORONARY SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 69. SOUTH KOREA ACUTE CORONARY SYNDROME MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 70. TAIWAN ACUTE CORONARY SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 71. TAIWAN ACUTE CORONARY SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 72. TAIWAN ACUTE CORONARY SYNDROME MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 73. THAILAND ACUTE CORONARY SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. THAILAND ACUTE CORONARY SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 75. THAILAND ACUTE CORONARY SYNDROME MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 76. VIETNAM ACUTE CORONARY SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 77. VIETNAM ACUTE CORONARY SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 78. VIETNAM ACUTE CORONARY SYNDROME MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 79. EUROPE, MIDDLE EAST & AFRICA ACUTE CORONARY SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA ACUTE CORONARY SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA ACUTE CORONARY SYNDROME MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 82. EUROPE, MIDDLE EAST & AFRICA ACUTE CORONARY SYNDROME MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 83. DENMARK ACUTE CORONARY SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. DENMARK ACUTE CORONARY SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 85. DENMARK ACUTE CORONARY SYNDROME MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 86. EGYPT ACUTE CORONARY SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 87. EGYPT ACUTE CORONARY SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 88. EGYPT ACUTE CORONARY SYNDROME MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 89. FINLAND ACUTE CORONARY SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. FINLAND ACUTE CORONARY SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 91. FINLAND ACUTE CORONARY SYNDROME MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 92. FRANCE ACUTE CORONARY SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 93. FRANCE ACUTE CORONARY SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 94. FRANCE ACUTE CORONARY SYNDROME MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 95. GERMANY ACUTE CORONARY SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. GERMANY ACUTE CORONARY SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 97. GERMANY ACUTE CORONARY SYNDROME MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 98. ISRAEL ACUTE CORONARY SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 99. ISRAEL ACUTE CORONARY SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 100. ISRAEL ACUTE CORONARY SYNDROME MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 101. ITALY ACUTE CORONARY SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 102. ITALY ACUTE CORONARY SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 103. ITALY ACUTE CORONARY SYNDROME MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 104. NETHERLANDS ACUTE CORONARY SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 105. NETHERLANDS ACUTE CORONARY SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 106. NETHERLANDS ACUTE CORONARY SYNDROME MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 107. NIGERIA ACUTE CORONARY SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 108. NIGERIA ACUTE CORONARY SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 109. NIGERIA ACUTE CORONARY SYNDROME MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 110. NORWAY ACUTE CORONARY SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 111. NORWAY ACUTE CORONARY SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 112. NORWAY ACUTE CORONARY SYNDROME MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 113. POLAND ACUTE CORONARY SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 114. POLAND ACUTE CORONARY SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 115. POLAND ACUTE CORONARY SYNDROME MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 116. QATAR ACUTE CORONARY SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 117. QATAR ACUTE CORONARY SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 118. QATAR ACUTE CORONARY SYNDROME MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 119. RUSSIA ACUTE CORONARY SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 120. RUSSIA ACUTE CORONARY SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 121. RUSSIA ACUTE CORONARY SYNDROME MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 122. SAUDI ARABIA ACUTE CORONARY SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 123. SAUDI ARABIA ACUTE CORONARY SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 124. SAUDI ARABIA ACUTE CORONARY SYNDROME MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 125. SOUTH AFRICA ACUTE CORONARY SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 126. SOUTH AFRICA ACUTE CORONARY SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 127. SOUTH AFRICA ACUTE CORONARY SYNDROME MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 128. SPAIN ACUTE CORONARY SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 129. SPAIN ACUTE CORONARY SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 130. SPAIN ACUTE CORONARY SYNDROME MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 131. SWEDEN ACUTE CORONARY SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 132. SWEDEN ACUTE CORONARY SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 133. SWEDEN ACUTE CORONARY SYNDROME MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 134. SWITZERLAND ACUTE CORONARY SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 135. SWITZERLAND ACUTE CORONARY SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 136. SWITZERLAND ACUTE CORONARY SYNDROME MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 137. TURKEY ACUTE CORONARY SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 138. TURKEY ACUTE CORONARY SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 139. TURKEY ACUTE CORONARY SYNDROME MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 140. UNITED ARAB EMIRATES ACUTE CORONARY SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 141. UNITED ARAB EMIRATES ACUTE CORONARY SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED ARAB EMIRATES ACUTE CORONARY SYNDROME MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED KINGDOM ACUTE CORONARY SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED KINGDOM ACUTE CORONARY SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 145. UNITED KINGDOM ACUTE CORONARY SYNDROME MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 146. ACUTE CORONARY SYNDROME MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 147. ACUTE CORONARY SYNDROME MARKET, FPNV POSITIONING MATRIX, 2023